By Fineline Cube 
China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced that the multi-center, 24-week Phase IIb study for its oral small-molecule GLP-1 receptor agonist (GLP-1RA), MDR-001, has reached the clinical endpoints. The results showed that obese or overweight subjects receiving MDR-001 achieved a weight loss of up to 10.3% after 24 weeks of treatment, compared to 2.5% in the placebo group (P<0.00001). The placebo-adjusted average weight loss ranged from -7.1% to -7.8%, with excellent safety and tolerability.
Clinical Performance
MDR-001 demonstrated outstanding efficacy and safety in the Phase IIb clinical study. These results fully validate the exceptional capabilities of MindRank’s new drug R&D team and the high efficiency of its self-developed AI drug discovery platform, Molecule Pro.
Dosage Progress
The company has also made significant progress in clinical trials exploring a once-daily dosing regimen for MDR-001.-Fineline Info & Tech